Shore Capital is delighted to be appointed as Joint Corporate Broker to Destiny Pharma plc (AIM: DEST).

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and clinical assets for the prevention of C. difficile infection recurrence, which is the leading cause of hospital acquired infection in the US, and the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.

For further information please contact:  

Shore Capital +44 (0) 20 7408 4090

Corporate Advisory: Daniel Bush / James Thomas / Lucy Bowden

Corporate Broking: Cameron Gammon

For Shore Capital media enquiries, please contact:  

Will Poulton: +44 (0)74 8038 3738